No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Pharmaceuticals
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
www.simcere.comNo one on the platform currently holds 2096.HK.
No tracked institution reports a position in 2096.HK as of their last filing.
No one on the platform has traded 2096.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 19.6% | 15.3% | 16.5% | — | — | — |
| Rev. Growth % | 16.5% | 11.4% | ||||
| Profit Margin % | 17.4% | 16.8% | 14.7% | |||
| Free Cash Flow Margin % | 14.9% | 2.9% | 5.2% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.5B | +36.9% | $0.69 | $0.58–$0.96 | — | 4 |
| 2027 | $12.3B | +17.2% | $0.84 | $0.75–$0.92 | — | 4 |
| 2028 | $14.2B | +15.5% | $0.96 | $0.89–$1.02 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 2096.HKSimcere Pharmaceutical Group Limited | $11.17 | -0.71% | $28.7B | — |
| 0512.HKGrand Pharmaceutical Group Limited | $4.99 | +1.63% | $17.5B | — |
| 0867.HKChina Medical System Holdings Limited | $11.05 | +1.38% | $26.9B | — |
| 1513.HKLivzon Pharmaceutical Group Inc. | $20.82 | +0.10% | $22.8B | — |
| 1548.HKGenscript Biotech Corporation |
| $32.56 |
| +0.56% |
| $71.1B |
| — |
| 1877.HKShanghai Junshi Biosciences Co., Ltd. | $16.98 | -1.74% | $23.9B | — |
| 2696.HKShanghai Henlius Biotech, Inc. | $57.35 | -3.21% | $31.2B | — |
Source: Financial Modeling Prep · peers by sector/industry